{"id":"W4392246441","doi":"10.1016/j.esmoop.2024.102358","title":"30P OSE279, a PD-1-blocking monoclonal antibody, as future backbone of a bifunctional checkpoint inhibitor platform: Preliminary results of a first-in-human (FIH) study in subjects with advanced malignancies","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; Genentech; Sierra Oncology; Daiichi Sankyo Europe; Servier; Eisai; Astellas Pharma; Basilea Pharmaceutica; PharmaMar; European Society for Medical Oncology; Pfizer; Incyte; Boston Pharmaceuticals; Agios Pharmaceuticals; Ipsen; Eisai Canada; BeiGene; Clovis Oncology; Les Laboratories Pierre Fabre; Loxo Oncology; Astex Pharmaceuticals; Bayer HealthCare; Exelixis; Sanofi; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Monoclonal antibody; Blocking (statistics); Bifunctional; Medicine; Cancer research; Blocking antibody; Antibody; Immunology; Chemistry; Computer science","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007385117,0.0002486403,0.0005806064,0.0003701011,0.00006399563,0.00003737425,0.0002251688,0.0001096428,0.0001383567],"category_scores_gemma":[0.00003966849,0.0001908288,0.0001019927,0.0008420238,0.0001238809,0.0003195428,0.0001731631,0.000291354,0.000003291764],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001730723,"about_ca_system_score_gemma":0.0003829614,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00491582,"about_ca_topic_score_gemma":0.006317617,"domain_scores_codex":[0.9979984,0.00004557535,0.0007517592,0.0004823522,0.0004462825,0.0002756772],"domain_scores_gemma":[0.9992131,0.00009767319,0.0001920925,0.0003443536,0.00009441222,0.00005835429],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4441684,0.008536345,0.3190948,0.003588077,0.001997977,0.004042048,0.04758566,0.0005017761,0.1541295,0.000408035,0.002820641,0.0131267],"study_design_scores_gemma":[0.02494767,0.01526415,0.9026259,0.007634132,0.0001164544,0.0002200491,0.009951081,0.000208884,0.03612429,0.0001307132,0.002381688,0.0003950588],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943765,0.001194061,0.000004166629,0.000681886,0.0002307265,0.001916998,0.00004844975,0.00002612346,0.001521041],"genre_scores_gemma":[0.9984065,0.000103841,0.0004181319,0.00005606145,0.0001355413,0.0001215337,0.00009818377,0.00003547337,0.0006247801],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.583531,"threshold_uncertainty_score":0.7781774,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02055486266362737,"score_gpt":0.3161936157273622,"score_spread":0.2956387530637348,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}